Immix Biopharma Inc. (IMMX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing removes capital overhang, strengthens negotiating position, and supports a clear path toward BLA submission in mid-2026. With reasonable peak revenue scenarios ranging from $320 million to over $1 billion annually, the current sub-$400 million valuation presents further upside.
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
Immix Biopharma has provided only faint early signals of its flagship CAR T-cell therapy in AL amyloidosis. However, an upcoming data presentation at ASH should shed more light on the prospects of a potential FDA submission in 2026. Cash remains an issue, although IMMX has secured funding through a strategic investment to get them through the next few quarters.
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immix Biopharma Inc. (IMMX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Immix Biopharma Inc. ever had a stock split?
Immix Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ilya Rachman MBA, CEO | NASDAQ (CM) Exchange | 45258H106 CUSIP |
| US Country | 18 Employees | - Last Dividend | - Last Split | 16 Dec 2021 IPO Date |
Overview
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical entity focusing on the creation of tissue-specific treatments aimed at addressing unmet needs in oncology and inflammation. Operating out of Los Angeles, California, with activities spanning the United States and Australia, the company is at the forefront of developing innovative therapeutic solutions. With its inception in 2012, Immix Biopharma has established itself as a pioneer in leveraging tissue-specific targeting to enhance the efficacy and safety profiles of its therapeutic candidates. Through its collaborative efforts with industry partners such as BeiGene Ltd., Immix Biopharma is pushing the boundaries of clinical development with its lead compounds in a bid to tackle some of the most challenging diseases facing patients today.
Products and Services
- IMX-110
- IMX-111
- IMX-120
- Clinical Collaboration and Supply Agreement with BeiGene Ltd.
Currently in Phase 1b/2a clinical trials, IMX-110 is Immix Biopharma’s flagship candidate, focused on the treatment of soft tissue sarcoma and solid tumors. This compound exemplifies the company’s commitment to developing tissue-specific therapeutics designed to attack cancer cells more effectively while minimizing impact on healthy tissues.
IMX-111 represents a cutting-edge biologic therapy under development for the treatment of colorectal cancers. This tissue-specific biologic aims to deliver targeted therapeutic effects directly to the cancer cells, thus offering a potentially more precise and less toxic treatment option for patients grappling with this common yet challenging type of cancer.
Focused on the treatment of inflammatory bowel diseases, including ulcerative colitis and severe Crohn’s disease, IMX-120 is a testament to Immix Biopharma’s dedication to addressing inflammation with innovative biologic therapies. As a tissue-specific therapeutic, IMX-120 is designed to directly target the sites of inflammation, offering hope for more effective and safer treatment modalities for patients suffering from these debilitating conditions.
Immix Biopharma has entered into a pivotal clinical collaboration and supply agreement with BeiGene Ltd. This collaboration focuses on conducting a combination Phase 1b clinical trial exploring the synergistic potential of IMX-110 in conjunction with Tislelizumab, an anti-PD-1 therapy, for the treatment of solid tumors. Such collaborative ventures underscore Immix Biopharma’s strategy of partnering with leading global pharmaceutical entities to accelerate the development and enhance the potential of its innovative therapeutic pipeline.
Contact Information
